Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Future Trajectory | Analysts project varied outcomes, with price targets ranging from $8 to $11, as Bausch Health navigates debt challenges and growth opportunities |
Strategic Maneuvers | Delve into Bausch Health's initiatives to maximize shareholder value, including the potential separation of its Bausch+Lomb division |
Debt Dilemma | Explore the company's $21.5 billion debt burden and its impact on financial stability, including market reactions to potential bankruptcy rumors |
Financial Resilience | Bausch Health's Q3 2024 results showcase robust growth, with revenues of $2.51 billion and a 12% year-over-year increase, surpassing analyst expectations |
Metrics to compare | BHC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBHCPeersSector | |
|---|---|---|---|---|
P/E Ratio | 13.7x | 19.7x | −0.5x | |
PEG Ratio | 0.03 | 0.11 | 0.00 | |
Price / Book | −3.9x | 1.5x | 2.6x | |
Price / LTM Sales | 0.2x | 2.1x | 3.2x | |
Upside (Analyst Target) | 40.8% | 63.5% | 45.7% | |
Fair Value Upside | Unlock | 31.5% | 4.8% | Unlock |